If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Keep me logged in Forgot your password?

Please wait...

Please wait...

 Overactive Bladder

Fesoterodine Relieves Nocturnal Urgency in OAB Patients

May 23, 2012

Flexible-dose fesoterodine is superior to placebo in decreasing the number of nocturnal urgency episodes and nocturnal micturitions in patients with overactive bladder (OAB), researchers reported at the American Urological Association 2012 annual meeting.
 

OAB Patients Most Bothered by Urgency

May 23, 2012

Patients with overactive bladder (OAB) say they are most bothered by symptoms of urinary urgency either as a primary complaint or as a driving symptom for frequency, according to a pilot study presented at the American Urological Association 2012 annual meeting.
 

BoNTA Safe, Effective for Diabetic OAB Patients

May 23, 2012

Diabetes has no influence on intravesical botulinum toxin type A (BoNTA) injection in overactive bladder (OAB) patients, researchers reported at the American Urological Association 2012 annual meeting.
 

Oxybutynin Gel Eases Urinary Incontinence

May 21, 2012

A new oxybutynin gel (OTG) with propylene glycol to aid transdermal delivery, which dispensed via a pump, is effective for treating urgency and mixed urinary incontinence (UI), according to the findings of a phase 3 study presented at the American Urological Association 2012 annual meeting.
 

OAB Sufferers Less Physically Active

May 19, 2012

Men and women with overactive bladder (OAB) are significantly less likely to achieve recommended physical activity levels than those with no or minimal symptoms (NMS) of OAB, according to a poster presentation at the American Urological Association 2012 annual meeting.
 

Transdermal Gel for Overactive Bladder Launched

April 27, 2012

Watson Pharmaceuticals of Parsippany, N.J., and Antares Pharma. Inc. of Ewing, NJ, have announced the launch of Gelnique (oxybutynin), a transdermal gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency.
 

Novel Drug for Overactive Bladder Works Even If Antimuscarinics Do Not

February 29, 2012

PARIS—Mirabegron, an experimental drug for overactive bladder (OAB), can effectively treat the condition in patients whether or not they failed previous antimuscarinic therapy, according to findings presented at the 27th Annual Congress of the European Association of Urology.
 

Repeated Toxin Injections Safe and Effective for Refractory Overactive Bladder

December 26, 2011

Repeated injections of botulinum toxin type A (BoNTA) are safe and effective for the medium-term management of refractory overactive bladder (OAB) and idiopathic detrusor overactivity (IDO), according to British investigators.
 

Overactive Bladder Linked to Metabolic Syndrome in Women

November 01, 2011

Metabolic syndrome is associated with overactive bladder (OAB) in women, according to researchers.
 

Botulinum Toxin Effective in OAB Patients without Detrusor Overactivity

August 31, 2011

GLASGOW—Intravesical botulinum toxin may be an effective treatment for overactive bladder (OAB) without detrusor overactivity (DOA) on urodynamic assessment, researchers reported at the International Continence Society annual meeting.
 

Approval Sought for New Overactive Bladder Drug

August 29, 2011

If cleared by the FDA, mirabegron would be the first oral treatment with a new mechanism of action for OAB in almost 30 years.
 

Antibiotics May Improve Treatment of Overactive Bladder

August 29, 2011

GLASGOW—Antibiotics may be a useful adjunctive treatment for overactive bladder (OAB), according to British researchers.
 

Trigonal Injections of Botulinum Toxin Improve OAB Outcomes

May 18, 2011

WASHINGTON, D.C.—Trigonal intradetrusor injections of botulinum toxin-A (BTX-A) results in greater reduction in overactive bladder (OAB) symptoms compared with trigone-sparing BTX-A injections, Irish investigators reported at the American Urological Association 2011 annual meeting.
 

Overactive Bladder Often Associated with Pelvic Organ Prolapse

May 18, 2011

WASHINGTON, D.C.—Posterior compartment pelvic organ prolapse (POP) in women is often associated with overactive bladder (OAB), and POP surgery may help to decrease OAB symptoms as well as detrusor overactive (DO), according to study findings presented at the American Urological Association 2011 annual meeting.
 

Surrogate Markers May Identify Age-Associated Biochemical Changes in OAB patients

May 18, 2011

WASHINGTON, D.C.—Urinary nerve growth factor (NGF) and MCP-1 may be surrogate markers for monitoring age-associated biochemical changes in patients with overactive bladder (OAB), according to data presented at the American Urological Association 2011 annual meeting.
 

'OAB-Dry' May Need to be Reassessed

May 17, 2011

WASHINGTON, D.C.—Questionnaires used to diagnose patients with overactive bladder (OAB) may identify anyone with polyuria, bladder hypersensitivity, and even OAB-wet with rare leakage episodes as OAB-dry, investigators reported at the American Urological Association 2011 annual meeting.
 

Overactive Bladder Found in One Fifth of Type 2 Diabetics

May 17, 2011

WASHINGTON, D.C—Japanese researchers found that more than one fifth of patients with type 2 diabetes receiving care at a dedicated diabetes center have overactive bladder (OAB).
 

Nocturia Is the Most Bothersome OAB Symptom in POTS Patients

May 17, 2011

WASHINGTON, D.C.—Nocturia is the most common overactive bladder (OAB) symptom affecting health-related quality of life (HRQL) in patients with postural tachycardia syndrome (POTS), investigators reported at the American Urological Association 2011 annual meeting.
 

Parkinson's Severity Associated with OAB Symptoms

May 17, 2011

WASHINGTON, D.C.—Overactive bladder (OAB) symptoms are common in patients with Parkinson's disease regardless of age and gender, and the severity of Parkinson's symptoms correlates with OAB symptoms, according to a study presented at the American Urological Association 2011 annual meeting.
 

OAB Symptoms Linked to Elevated Serum Leptin

May 16, 2011

WASHINGTON, D.C.—Elevation of serum leptin and a decrease in monocyte chemotactic protein-1 (MCP-1) levels are associated with overactive bladder (OAB) symptoms, according to new data presented at the American Urological Association 2011 annual meeting.
 

Sacral Neuromodulation Found Effective and Well-Tolerated

May 16, 2011

WASHINGTON, D.C.—Sacral neuromodulation with InterStim Therapy is safe and well tolerated as a treatment for patients with overactive bladder and those with urinary retention, French investigators reported at the American Urological Association 2011 annual meeting.
 

Adverse Events Common After Botulinum Toxin Injections

May 16, 2011

WASHINGTON, D.C.—Adverse events (AEs) after intravesical botulinum toxin type A for idiopathic detrusor overactivity (IDO) are encountered frequently, according to a new study presented at the American Urological Association 2011 annual meeting.
 

Botulinum Toxin Effective Long Term for Severe OAB

May 16, 2011

WASHINGTON, D.C.—Detrusor botulinum toxin type A injections are a safe and effective treatment long-term for patients with severe overactive bladder (OAB), Swiss researchers reported at the American Urological Association 2011 annual meeting.
 

OAB Affects Work Productivity

May 15, 2011

WASHINGTON, D.C.—Men and women who suffer from overactive bladder (OAB) report significantly greater levels of work limitations compared with those without urinary symptoms, according to a new study presented at the American Urological Association 2011 annual meeting.
 

Remission of Urologic Symptoms Not Uncommon

May 15, 2011

WASHINGTON, D.C.—The natural history of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) may involve as much remission as progression, according to a new longitudinal study presented at the American Urological Association 2011 annual meeting.
 

Overactive Bladder Highly Prevalent, Study Finds

May 14, 2011

WASHINGTON, D.C.—Overactive bladder (OAB) is highly prevalent in both women and men and the prevalence varies by race and ethnicity, according to study findings presented at the American Urological Association 2011 annual meeting.
 

BoNT-A Efficacy for Idiopathic Detrusor Overactivity Confirmed

March 21, 2011

VIENNA—Findings from a large randomized trial confirm the effectiveness of botulinum toxin type A (BoNT-A) for refractory idiopathic detrusor overactivity (IDO) in women.
 

Healthy Habits May Improve Urinary, Sexual Function

November 02, 2010

SAN FRANCISCO—Healthy lifestyle choices, such as not smoking and exercising regularly, may significantly impact urinary and sexual function, two studies suggest.
 

Fesoterodine for OAB Shows Efficacy at One Week

October 18, 2010

In a recent study, fesoterodine showed rapid onset of efficacy at one week in patients with overactive bladder (OAB) who were previously treated with tolterodine and dissatisfied with that drug.
 

Potential Gene Biomarkers for OAB Identified

September 01, 2010

TORONTO—An analysis of gene-expression patterns in women with overactive bladder (OAB) may point the way to possible new biomarkers for the condition.
 
Popular Topics
Acute Kidney Injury AKI Androgen Deprivation Anemia Benign Prostatic Hyperplasia Bladder Cancer BPH Cardiovascular Disease Chronic Kidney Disease Circumcision CKD CVD Dialysis End-stage Renal Disease Hemodialysis Kidney Cancer Overactive Bladder Prostate Cancer PSA Renal Cell Carcinoma Reproductive Medicine Secondary Hyperparathyroidism Transplantation Urinary Incontinence Urology

 

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions